Elmiron (pigmentary maculopathy)
Long-term use of Elmiron, a bladder-pain medication, has been tied to retinal damage in its FDA label. The federal case group is mostly resolved, so we provide information only.
- Case group
- MDL 2973
- Court
- D. New Jersey
- Centralized
- Dec 15, 2020
- Pending cases
- 186Oct 1, 2026
We're not accepting review requests here
MDL 2973 is winding down (186 pending of 1,989 total) with ongoing confidential settlements.
See campaigns accepting reviewsWhere things stand
New to federal case groups? Read what an MDL is and how a mass tort claim works.
- Jun 2020FDA approved label warning of pigmentary maculopathy with long-term use.
- Sep 1, 2026Pending actions down to 286 from 1,988 historical.
Records that usually help
You don't need these to start. Don't upload them here. A firm will ask if it needs them.
- Pharmacy records for Elmiron
- Retina/ophthalmology exam records, OCT imaging
- Urology records for IC treatment
- Vision-related impact documentation
About filing deadlines
Deadlines to file a claim vary by state and situation, and some may already have passed. Only a licensed attorney can tell you whether a deadline applies to you. Submitting here does not stop any deadline. Read how filing deadlines work.
Related campaigns
Attorney advertising. TortMatics (FusionByte Media LLC) is not a law firm. Information on this page is general and is not medical or legal advice. Talk to a doctor before changing any medication.